Abstract 1942P
Background
B-MPT accounts for <1% of breast neoplasms. The standard treatment for non-metastatic disease consists of wide local excision. Type of excision and adjuvant treatments are still matter of debate. Because of its rarity, only few case series with less than 100 B-MPT patients (pts) are available.
Methods
We conducted a retrospective single-centre observational study to describe outcomes and possible prognostic factors of pts with B-MPT. Data of consecutive patients aged ³18 years old, with a histologically confirmed diagnosis of non-metastatic B-MPT, who underwent surgery from January 2000 to December 2021, were collected. The primary endpoint was recurrence-free survival (RFS). Survival was calculated using Kaplan–Meier method. Multivariable analysis was performed with Cox proportional hazards model (significance at p-value<0.05).
Results
131 pts were included. Patient characteristics are reported in table. All patients received a surgery, 5 adjuvant anthracycline-based chemotherapy and 15 radiation therapy. After a median follow-up of 6.8 years, 36 (28%) pts experienced a disease recurrence: 19 (15%) a distant and 23 (18%) a loco-regional relapse. The median RFS, distant RFS (DRFS) and local RFS (LRFS) were not reached. The 5-year RFS, DRFS and LRFS rates were of 72%, 85% and 82%. At univariate analysis DRFS significantly correlated with the presence of at least one negative pathological prognostic factor (i.e., Size >5 cm, Multifocal disease or Heterologous differentiation [SMH]) (p=.03). If adjusted for type of breast surgery, SMH was associated also with LRFS (HR 3.3; 95%CI, 1.4-7.8; p=.008). The type of surgery was not prognostic for RFS, DRFS and LRFS.
Table: 1942P
Patient characteristics
N=131 | |
Age at diagnosis, mean (DS) | 46.7 (12.7) |
Negative pathological prognostic factors | |
Size >5 cm - % | 43% |
Multifocal disease - % | 11% |
Heterologous differentiation - % | 20% |
At least one negative prognostic factor - % | 62% |
Surgery strategy | |
Upfront wide local excision with attention to margins - % | 45% |
Re-excision after previous inadequate resection - % | 46% |
Inadequate resection without re-excision - % | 9% |
Type of last breast surgery | |
Excisional biopsy (no attempt at margins) - % | 9% |
Lumpectomy (wide local excision with attention to margins) - % | 34% |
Mastectomy - % | 57% |
pR1 - % | 14% |
Adjuvant chemotherapy - % | 4% |
Adjuvant radiotherapy - % | 11% |
Conclusions
Natural history of B-MPT is burdened by local and distant recurrences. Pathological features more than the type of wide local excision seem to represent the most significant prognostic factor for recurrences.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
1939P - phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients
Presenter: Sant Chawla
Session: Poster session 15
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15